Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:HBPCFNASDAQ:IMRXNASDAQ:NKTXNASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHBPCFHelix Biopharma$0.60$0.60$0.59▼$0.60$31.81M-0.131 shsN/AIMRXImmuneering$3.39-5.6%$2.00$1.00▼$3.87$122.01M0.382.56 million shs908,546 shsNKTXNkarta$1.76+0.9%$1.84$1.31▼$8.23$124.54M0.71.04 million shs274,388 shsSGMOSangamo Therapeutics$0.54+0.2%$0.54$0.31▼$3.18$124.98M1.239.06 million shs1.98 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHBPCFHelix Biopharma0.00%0.00%0.00%+31.90%+335.73%IMRXImmuneering0.00%-3.97%+59.15%+151.11%+211.01%NKTXNkarta0.00%+5.72%-7.63%+12.50%-66.12%SGMOSangamo Therapeutics0.00%-0.91%+1.13%-24.18%+66.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AIMRXImmuneering4.0853 of 5 stars3.34.00.00.04.25.00.6NKTXNkarta2.0921 of 5 stars3.61.00.00.01.91.70.6SGMOSangamo Therapeutics2.7098 of 5 stars3.34.00.00.02.40.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHBPCFHelix Biopharma 0.00N/AN/AN/AIMRXImmuneering 2.60Moderate Buy$13.25290.86% UpsideNKTXNkarta 3.13Buy$14.33716.71% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$4.50739.55% UpsideCurrent Analyst Ratings BreakdownLatest HBPCF, NKTX, IMRX, and SGMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/10/2025NKTXNkartaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/15/2025NKTXNkartaWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform5/15/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/14/2025SGMOSangamo TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.005/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/AIMRXImmuneering$320K381.27N/AN/A$1.33 per share2.55NKTXNkartaN/AN/AN/AN/A$5.78 per shareN/ASGMOSangamo Therapeutics$57.80M2.16N/AN/A$0.11 per share4.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHBPCFHelix Biopharma-$6.82M-$0.14N/A∞N/AN/AN/A-747.46%N/AIMRXImmuneering-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)NKTXNkarta-$108.79M-$1.51N/AN/AN/AN/A-26.64%-21.62%8/12/2025 (Estimated)SGMOSangamo Therapeutics-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/5/2025 (Estimated)Latest HBPCF, NKTX, IMRX, and SGMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/16/2025Q3 2025HBPCFHelix BiopharmaN/A-$0.02N/A-$0.02N/AN/A5/14/2025Q1 2025NKTXNkarta-$0.44-$0.43+$0.01-$0.43N/AN/A5/12/2025Q1 2025SGMOSangamo Therapeutics-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHBPCFHelix BiopharmaN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHBPCFHelix BiopharmaN/A0.420.42IMRXImmuneeringN/A7.487.48NKTXNkartaN/A14.4814.48SGMOSangamo TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHBPCFHelix BiopharmaN/AIMRXImmuneering67.65%NKTXNkarta80.54%SGMOSangamo Therapeutics56.93%Insider OwnershipCompanyInsider OwnershipHBPCFHelix Biopharma7.60%IMRXImmuneering22.90%NKTXNkarta8.40%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHBPCFHelix Biopharma953.02 million48.99 millionNot OptionableIMRXImmuneering6035.99 million27.75 millionNot OptionableNKTXNkarta14070.96 million65.00 millionOptionableSGMOSangamo Therapeutics480233.17 million223.61 millionOptionableHBPCF, NKTX, IMRX, and SGMO HeadlinesRecent News About These CompaniesH.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy DataJuly 3, 2025 | msn.comSGMO - Sangamo Therapeutics Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Consensus PT from BrokeragesJune 27, 2025 | americanbankingnews.comSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - MorningstarJune 25, 2025 | morningstar.comMSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business WireJune 25, 2025 | businesswire.comSangamo cues up Fabry gene therapy filing on STAAR dataJune 25, 2025 | pharmaphorum.comPSangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseJune 24, 2025 | finanznachrichten.deSangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational dataJune 24, 2025 | fiercebiotech.comFSangamo rises after trial data for Fabry disease therapyJune 24, 2025 | msn.comSangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC WainwrightJune 24, 2025 | marketbeat.comSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseJune 24, 2025 | businesswire.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Moderate Buy" by BrokeragesJune 24, 2025 | marketbeat.comH.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO)May 31, 2025 | insidermonkey.comSangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same DayMay 12, 2025 | finance.yahoo.comSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 12, 2025 | businesswire.comSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingMay 12, 2025 | businesswire.comSangamo Therapeutics Q1 2025 Earnings PreviewMay 12, 2025 | msn.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 5.70%May 10, 2025 | aaii.comASangamo Therapeutics Sets Sights on 2026 BLA Filing for Fabry Disease Gene TherapyMay 7, 2025 | precisionmedicineonline.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHBPCF, NKTX, IMRX, and SGMO Company DescriptionsHelix Biopharma OTCMKTS:HBPCF$0.60 0.00 (0.00%) As of 07/3/2025Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Immuneering NASDAQ:IMRX$3.39 -0.20 (-5.57%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$3.38 -0.02 (-0.44%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Nkarta NASDAQ:NKTX$1.76 +0.02 (+0.86%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$1.76 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Sangamo Therapeutics NASDAQ:SGMO$0.54 +0.00 (+0.19%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$0.53 -0.01 (-1.31%) As of 07/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.